Subgroup analysis of phase 3 LUX-H&N1 trial: Afatinib versus methotrexate for head and neck squamous cell carcinoma
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Makoto Tahara, MD, PhD, from National Cancer Center Hospital East, Kashi...
Author: EMJ
Added: 02/20/2016
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | HNSCC | Hospitals | Methotrexate | Politics | Skin Cancer | Squamous Cell Carcinoma